NICE has issued draft guidance recommended brodalumab (Kyntheum, Leo Pharma) for adults with severe psoriasis which has not responded to other systemic therapies.

The committee concluded that compared with most other biological treatments, or with apremilast and dimethyl fumarate, brodalumab is generally more cost effective.

Patients can self-inject brodalumab. It is recommended at a confidential discount price.
NICE also recently recommended ixekizumab (Taltz, Eli Lilly) and dimethyl fumarate (Skilarence, Almirall) for adults with this type of severe psoriasis.

Brodalumab is recommended as an option for treating plaque psoriasis in adults, only if:

  • The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
  • The disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated and
  • The company provides the drug with the discount agreed in the patient access scheme.

NICE also recently recommended ixekizumab (Taltz, Eli Lilly) and dimethyl fumarate (Skilarence, Almirall) for adults with this type of severe psoriasis.

For more information visit https://www.nice.org.uk/guidance/indevelopment/gid-ta10220/documents